新医学
新醫學
신의학
NEW CHINESE MEDICINE
2014年
5期
297-299
,共3页
重组人白细胞介素-11衍生物%重组人白细胞介素-11%化学治疗%血小板减少
重組人白細胞介素-11衍生物%重組人白細胞介素-11%化學治療%血小闆減少
중조인백세포개소-11연생물%중조인백세포개소-11%화학치료%혈소판감소
rhIL-11 derivatives%rhIL-11%Chemotherapy%Thrombocytopenia
目的：评价注射用重组人IL-11（rhIL-11）衍生物及rhIL-11对恶性肿瘤化学治疗后血小板减少的疗效及安全性。方法收集恶性肿瘤化学治疗后出现Ⅲ～Ⅳ度血小板减少（≤50×109/L）患者63例，随机分为治疗组32例与对照组31例，于化学治疗结束后24～48 h开始，治疗组给予rhIL-11衍生物1.5 mg/d，对照组给予rhIL-113 mg/d，以血小板升至100×109/L为停药标准，比较两组血小板升至75×109/L 的时间及血小板升至100×109/L的时间，观察用药期间的不良反应发生情况。结果治疗组血小板升至75×109/L 的用药时间为（6.46±2.27）d，对照组血小板升至75×109/L的用药时间为（8.59±3.78）d，两组比较差异有统计学意义（P＜0.01）。治疗组血小板升至100×109/L的用药时间为（9.07±2.45）d；对照组血小板升至100×109/L的用药时间为（11.59±2.78）d，两组比较差异有统计学意义（P＜0.01）。两组不良反应发生率比较差异无统计学意义（P＞0.05）。结论 rhIL-11衍生物与rhIL-11对恶性肿瘤化学治疗后引起的血小板减少疗效确切。与rhIL-11相比，rhIL-11衍生物起效迅速，更有优势。
目的：評價註射用重組人IL-11（rhIL-11）衍生物及rhIL-11對噁性腫瘤化學治療後血小闆減少的療效及安全性。方法收集噁性腫瘤化學治療後齣現Ⅲ～Ⅳ度血小闆減少（≤50×109/L）患者63例，隨機分為治療組32例與對照組31例，于化學治療結束後24～48 h開始，治療組給予rhIL-11衍生物1.5 mg/d，對照組給予rhIL-113 mg/d，以血小闆升至100×109/L為停藥標準，比較兩組血小闆升至75×109/L 的時間及血小闆升至100×109/L的時間，觀察用藥期間的不良反應髮生情況。結果治療組血小闆升至75×109/L 的用藥時間為（6.46±2.27）d，對照組血小闆升至75×109/L的用藥時間為（8.59±3.78）d，兩組比較差異有統計學意義（P＜0.01）。治療組血小闆升至100×109/L的用藥時間為（9.07±2.45）d；對照組血小闆升至100×109/L的用藥時間為（11.59±2.78）d，兩組比較差異有統計學意義（P＜0.01）。兩組不良反應髮生率比較差異無統計學意義（P＞0.05）。結論 rhIL-11衍生物與rhIL-11對噁性腫瘤化學治療後引起的血小闆減少療效確切。與rhIL-11相比，rhIL-11衍生物起效迅速，更有優勢。
목적：평개주사용중조인IL-11（rhIL-11）연생물급rhIL-11대악성종류화학치료후혈소판감소적료효급안전성。방법수집악성종류화학치료후출현Ⅲ～Ⅳ도혈소판감소（≤50×109/L）환자63례，수궤분위치료조32례여대조조31례，우화학치료결속후24～48 h개시，치료조급여rhIL-11연생물1.5 mg/d，대조조급여rhIL-113 mg/d，이혈소판승지100×109/L위정약표준，비교량조혈소판승지75×109/L 적시간급혈소판승지100×109/L적시간，관찰용약기간적불량반응발생정황。결과치료조혈소판승지75×109/L 적용약시간위（6.46±2.27）d，대조조혈소판승지75×109/L적용약시간위（8.59±3.78）d，량조비교차이유통계학의의（P＜0.01）。치료조혈소판승지100×109/L적용약시간위（9.07±2.45）d；대조조혈소판승지100×109/L적용약시간위（11.59±2.78）d，량조비교차이유통계학의의（P＜0.01）。량조불량반응발생솔비교차이무통계학의의（P＞0.05）。결론 rhIL-11연생물여rhIL-11대악성종류화학치료후인기적혈소판감소료효학절。여rhIL-11상비，rhIL-11연생물기효신속，경유우세。
Objective To evaluate the efficacy and side effect of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. Methods A total of 63 malignant tumor patients with grade Ⅲ-Ⅳ thrombocytopenia (≤50 ×1 09/L)after chemotherapy were collected and divided into treatment group and control group. At 24-48 hours after chemotherapy,the patients in treatment group received rhIL-11 derivatives 1.5 mg per day,while the patients in control group receive-drhIL-11 3 mg per day. The treatment would be ended when the platelets rose up to 1 00 ×1 09/L. The treat-ment time taken to get platelet rise up to 75 ×1 09/L or 1 00 ×1 09/L was compared between two groups. Ad-verse effects were observed during the treatment. Results There was a significant difference in the treatment time used to raise platelet up to 75 ×1 09/L between the treatment group (6.46 ±2.27)days and the control group (6.46 ±2.27)days (P<0.01 ). There was also a significant difference in the treatment time used to raise platelet up to 1 00 ×1 09/L between the treatment group (9.07 ±2.45 )days and the control group (11.59 ±2.78)days (P<0.01 ). The incidences of adverse effects between two groups showed no significant difference (P>0.05 ). Conclusion Bothe rhIL-11 derivatives and rhIL-11 are effective in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. The rhIL-11 derivatives has a more rapid effect to exhibit a slight advantage over rhIL-11.
